Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of the Combination of PI3K Inhibitor BAY 80-6946 and Allosteric-MEK Inhibitor BAY 86-9766 in Subjects With Advanced Cancer

NCT01392521 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01392521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of the Combination of PI3K Inhibitor BAY 80-6946 and Allosteric-MEK Inhibitor BAY 86-9766 in Subjects With Advanced Cancer
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
April 30, 2014
Enrollment
64 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms